–
Доклады на научных конференциях
-
- 2022 Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (Устный)
- Авторы: Abou-Alfa Ghassan K., Chan Stephen Lam, Kudo Masatoshi, Lau George, Kelley Robin Kate, Furuse Junji, Sukeepaisarnjaroen Wattana, Kang Yoon-Koo, Dao Tu V., De Toni Enrico N., Rimassa Lorenza, Breder Valeriy Vladimirovich, Vasilyev Alexander, Heurgue Alexandra, Tam Vincent, Mody Kabir, Thungappa Satheesh Chiradoni, He Philip, Negro Alejandra, Sangro Bruno
- ASCO GI 2022, Сан-Франциско, США, 21-23 января 2022